HIV-Associated Lipodystrophy Syndrome

Subscribe to Selected New Research on HIV-Associated Lipodystrophy Syndrome

66 relevant articles (2 outcomes, 10 trials/studies) found for this Disease

Description: Defective metabolism leading to fat maldistribution in patients infected with HIV. The etiology appears to be multifactorial and probably involves some combination of infection-induced alterations in metabolism, direct effects of antiretroviral therapy, and patient-related factors.

Also Known As:

HIV Lipodystrophy Syndrome; HIV-Associated Lipodystrophy; Lipodystrophy Syndrome, HIV; HIV Associated Lipodystrophy; HIV Associated Lipodystrophy Syndrome; Lipodystrophy Syndrome, HIV-Associated; Lipodystrophy, HIV-Associated

Relationship Network

Disease Context: Research Results

Related Diseases

1.	Lipodystrophy
2.	Insulin Resistance
3.	Dyslipidemias (Dyslipidemia)
4.	Obesity
5.	Type 2 Diabetes Mellitus (MODY)

Experts

1.	Rehman, Khaleel: 2 articles (07/2006 - 06/2005)
2.	Sekhar, Rajagopal V: 2 articles (07/2006 - 06/2005)
3.	Jahoor, Farook: 2 articles (07/2006 - 06/2005)
4.	Balasubramanyam, Ashok: 2 articles (07/2006 - 06/2005)
5.	Engelson, Ellen S: 2 articles (02/2004 - 05/2003)
6.	Kotler, Donald P: 2 articles (02/2004 - 05/2003)
7.	Albu, Jeanine B: 2 articles (02/2004 - 05/2003)
8.	Baldwin, Christine: 1 article (07/2008)
9.	Higgins, Nadine: 1 article (07/2008)
10.	Macallan, Derek C: 1 article (07/2008)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to HIV-Associated Lipodystrophy Syndrome:

1.	rosiglitazone (Avandia)FDA Link 04/01/2006 - "Evaluation of safety and efficacy of rosiglitazone in the treatment of HIV-associated lipodystrophy syndrome." 08/01/2005 - "OBJECTIVES: The insulin-sensitizer rosiglitazone is under investigation for therapy of HIV-associated lipodystrophy syndrome (LDS). " 07/01/2008 - "Treatment of altered body composition in HIV-associated lipodystrophy: comparison of rosiglitazone, pravastatin, and recombinant human growth hormone." Order ALL the reference details at left...
2.	AdiponectinIBA 11/01/2003 - "Adiponectin and HIV associated lipodystrophy." 12/15/2002 - "In this study, we sought to determine the relationship between serum levels of leptin and adiponectin (Acrp30) in patients with HIV-associated lipodystrophy (HIV-LD). " 02/01/2003 - "CONCLUSIONS: Plasma leptin and adiponectin levels are altered in the HIV lipodystrophy syndrome. " 02/01/2003 - "We examined the relationships of plasma leptin and adiponectin levels to fat distribution and insulin sensitivity in the HIV lipodystrophy syndrome. " 02/01/2004 - "This study tested the hypothesis that in patients with HIV-associated lipodystrophy, adiponectin levels were related to insulin resistance, TNF-alpha and IL-6 and treatment with nucleoside analogues. " Order ALL the reference details at left...
3.	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 02/01/2004 - "This study tested the hypothesis that in patients with HIV-associated lipodystrophy, adiponectin levels were related to insulin resistance, TNF-alpha and IL-6 and treatment with nucleoside analogues. " 09/01/2005 - "In the present study, we investigated the association between circulating levels of PAI-1 and locally produced PAI-1 in adipose tissue and body fat distribution and adipokines (TNF-alpha, TNF receptors, IL-6, IL-8) in patients with and without HIV-associated lipodystrophy syndrome (HALS). " Order ALL the reference details at left...
4.	Protease Inhibitors (Protease Inhibitor)IBA 01/01/2009 - "The role of protease inhibitors in the pathogenesis of HIV-associated lipodystrophy: cellular mechanisms and clinical implications." 10/19/2001 - "OBJECTIVE: To examine the relationships between protease inhibitor (PI) therapy, body fat distribution and metabolic disturbances in the HIV lipodystrophy syndrome. " 02/01/2004 - "HIV-associated lipodystrophy syndrome is a syndrome occurring in HIV-infected patients who were treated with highly-active antiretroviral therapy (HAART), especially regimen containing protease inhibitors. " 09/01/2009 - "Also, some HAART regimens in developed countries, especially those including protease inhibitors, have been shown to cause, in a high proportion of HIV-infected patients, a iatrogenic metabolic syndrome (HIV-lipodystrophy syndrome).This is associated with an increased risk of atherosclerosis-related cardiovascular events even in young HIV-infected people. " 07/01/2001 - "Antiretroviral treatment simplification with nevirapine in protease inhibitor-experienced patients with hiv-associated lipodystrophy: 1-year prospective follow-up of a multicenter, randomized, controlled study." Order ALL the reference details at left...
5.	Human Growth Hormone (Saizen)FDA LinkGeneric 05/01/2003 - "This study compared the relative changes in omental-mesenteric (OMAT) and retroperitoneal adipose tissues (RPAT) during therapy with recombinant human growth hormone (rhGH) in HIV-associated lipodystrophy. " 01/01/2008 - "Recombinant human growth hormone: rationale for use in the treatment of HIV-associated lipodystrophy." 02/01/2005 - "Use of recombinant human growth hormone in HIV-associated lipodystrophy." 08/01/2004 - "BACKGROUND: Treatment with high doses (2-6 mg day(-1)) of human growth hormone (hGH) in patients with human immunodeficiency virus (HIV)-associated lipodystrophy syndrome (HALS) has been shown to increase concentrations of total insulin-like growth-factor-I (IGF-I) more than twofold greater than the normal upper range and is accompanied by adverse effects such as joint pain and glucose intolerance. " 07/01/2008 - "Treatment of altered body composition in HIV-associated lipodystrophy: comparison of rosiglitazone, pravastatin, and recombinant human growth hormone." Order ALL the reference details at left...
6.	Insulin (Novolin)FDA Link 11/01/2007 - "The aim of this study was to analyze LPIN1 adipose tissue gene expression levels in 3 clinical insulin-resistant conditions-obesity, type 2 diabetes mellitus, and human immunodeficiency virus (HIV)-associated lipodystrophy-and its relationship with adipogenic and inflammatory markers. " 01/01/2007 - "HIV-associated lipodystrophy, arising as a result of long-term therapy with antiretroviral medications, is a complex syndrome characterized by changes in regional fat mass, dyslipidemia, and insulin sensitivity that, once established, is difficult to reverse. " 08/01/2005 - "OBJECTIVES: The insulin-sensitizer rosiglitazone is under investigation for therapy of HIV-associated lipodystrophy syndrome (LDS). " 04/01/2004 - "The circulating level of the inflammatory cytokine interleukin (IL)-6 is elevated in various insulin-resistant states including type 2 diabetes, obesity, cancer, and HIV-associated lipodystrophy. " 02/01/2003 - "We examined the relationships of plasma leptin and adiponectin levels to fat distribution and insulin sensitivity in the HIV lipodystrophy syndrome. " Order ALL the reference details at left...
7.	Glucose (Dextrose)FDA LinkGeneric 01/01/2007 - "Aims This review provides a brief summary of our current understanding of the epidemiology, clinical presentation and therapeutic approaches of what is termed 'the HIV-associated lipodystrophy syndrome' and of HIV-associated lipid and glucose metabolic abnormalities. " 09/01/2003 - "The human immunodeficiency virus (HIV)-lipodystrophy syndrome is characterized by abnormalities of lipid metabolism, glucose homeostasis, and fat distribution. " 05/01/2006 - "HIV-associated lipodystrophy syndrome is characterized by dyslipidemia, fat redistribution, and altered glucose metabolism; however, there has been little study of relationships between these risk factors for coronary heart disease (CHD) and lifestyle risks. " Order ALL the reference details at left...
8.	LeptinIBA 12/15/2002 - "In this study, we sought to determine the relationship between serum levels of leptin and adiponectin (Acrp30) in patients with HIV-associated lipodystrophy (HIV-LD). " 02/01/2003 - "CONCLUSIONS: Plasma leptin and adiponectin levels are altered in the HIV lipodystrophy syndrome. " 02/01/2003 - "We examined the relationships of plasma leptin and adiponectin levels to fat distribution and insulin sensitivity in the HIV lipodystrophy syndrome. " Order ALL the reference details at left...
9.	Metformin (Glucophage)FDA LinkGeneric 10/01/2008 - "Metformin increases HDL3-cholesterol and decreases subcutaneous truncal fat in nondiabetic patients with HIV-associated lipodystrophy." 07/26/2000 - "Metformin in the treatment of HIV lipodystrophy syndrome: A randomized controlled trial." 10/01/2008 - "The purpose of this study was to assess metformin effects on high-density lipoprotein (HDL) composition of patients with HIV-associated lipodystrophy (LDHIV). " Order ALL the reference details at left...
10.	Lipoproteins (Lipoprotein)IBA 10/01/2008 - "The purpose of this study was to assess metformin effects on high-density lipoprotein (HDL) composition of patients with HIV-associated lipodystrophy (LDHIV). " 01/01/2005 - "However, emerging abnormalities such as regional alterations in body shape (fat re-distribution syndrome or HIV-associated lipodystrophy), increasing body weight, high levels of low-density lipoprotein (LDL) cholesterol, insulin resistance, and other metabolic derangements may also be present. " Order ALL the reference details at left...

Therapies and Procedures

1.	Drug Therapy (Chemotherapy) 03/01/2004 - "Drug therapies that have been shown to be beneficial in other forms of lipodystrophy and are currently being evaluated in HIV-associated lipodystrophy are also discussed. " 03/01/2004 - "CONCLUSIONS: No drug therapy exists to fully ameliorate or correct the cosmetic changes of HIV-associated lipodystrophy. " Order ALL the reference details at left...
2.	Highly Active Antiretroviral Therapy (HAART) 01/01/2007 - "HIV-associated lipodystrophy or lipoatrophy, unreported before the introduction of highly active antiretroviral therapy (HAART), was first described in 1998, and has a prevalence ranging from 18% to 83%. " 06/01/2006 - "Approximately 30 - 50% of HIV-infected individuals after > or = 12 months on highly active antiretroviral therapy (HAART) may encounter the HIV-associated lipodystrophy syndrome (HALS), which attenuates patient compliance to this treatment. " 04/01/2006 - "BACKGROUND: HIV-associated lipodystrophy syndrome (LDS) as a long-term side effect of HAART is becoming increasingly important and negatively affects adherence to medication. " 02/27/2006 - "Following the introduction of highly active antiretroviral therapy (HAART), a number of metabolic and morphologic alterations, known as HIV-associated lipodystrophy syndrome (HALS), have been increasingly common in HIV-infected patients being treated with this therapy. " 02/01/2004 - "The authors report a 50-year old HIV-infected woman who developed HIV-associated lipodystrophy syndrome after 3 months of HAART. " Order ALL the reference details at left...
3.	Lipectomy (Liposuction) 03/01/2007 - "Surgical management of HIV-associated lipodystrophy: role of ultrasonic-assisted liposuction and suction-assisted lipectomy in the treatment of lipohypertrophy." 05/01/2001 - "METHODS: We present a patient with HIV lipodystrophy syndrome who underwent tumescent liposuction. " Order ALL the reference details at left...
4.	Injections 04/01/2004 - "METHODS: An HIV-associated lipodystrophy patient with facial lipoatrophy underwent multiple sessions of soft-tissue augmentation therapy with liquid injectable silicone (LIS) using the microdroplet serial puncture technique. " Order ALL the reference details at left...

Best Treatments:
Research Summary Report
on HIV-Associated Lipodystrophy Syndrome

*WARNING* This specific disease subtype has a relatively small number of significant evidence outcomes. You may proceed to order anyway, or go back to the search field and enter a more general type of the target illness. Once your report has been ordered, however, we can't refund the purchase.

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.

Free Updates for 1 Year
All 2 Outcomes
Top 200 Key Drugs and Biologics
Top 4 Key Therapies and Procedures
Detailed History Charts
Full Research Reference Details
Sample PDF Report on Psoriasis >>

Price:

$24.00 & Delivery via PDF download
updates for 1 year

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License Details >>

Price:

$490.00 access via web interface
1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m"
1 year subscription

Proceed to Checkout >>